"Rarecells, Inc...announced...the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests."
"Rarecells, Inc.,.announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET® -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome (MDS)...The study, expected to begin in Q1 2022, will be the first clinical evaluation of the ISET® -AML test."